Paolo Bucciarelli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7601177/publications.pdf

Version: 2024-02-01

87 papers 4,897 citations

36 h-index 95083 68 g-index

87 all docs

87 docs citations

times ranked

87

5015 citing authors

#	Article	IF	CITATIONS
1	Acquired von Willebrand Syndrome: Data from an International Registry. Thrombosis and Haemostasis, 2000, 84, 345-349.	1.8	327
2	Risk factors for venous and arterial thrombosis. Blood Transfusion, 2011, 9, 120-38.	0.3	294
3	Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology, 2006, 44, 1528-1534.	3.6	249
4	Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood, 2009, 113, 526-534.	0.6	239
5	Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology, 2005, 41, 603-608.	3.6	190
6	A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism. Blood, 2004, 104, 3631-3634.	0.6	179
7	Risk Factors and Recurrence Rate of Primary Deep Vein Thrombosis of the Upper Extremities. Circulation, 2004, 110, 566-570.	1.6	172
8	Interaction Between the G20210A Mutation of the Prothrombin Gene and Oral Contraceptive Use in Deep Vein Thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 700-703.	1.1	170
9	A Common Mutation in the Methylenetetrahydrofolate Reductase Gene (C677T) Increases the Risk for Deep-Vein Thrombosis in Patients With Mutant Factor V (Factor V:Q 506). Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 1662-1666.	1.1	161
10	Risk of Venous Thromboembolism and Clinical Manifestations in Carriers of Antithrombin, Protein C, Protein S Deficiency, or Activated Protein C Resistance. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 1026-1033.	1.1	145
11	Interleukin-10 and interleukin-6 gene polymorphisms as risk factors for Alzheimer's disease. Neurobiology of Aging, 2004, 25, 1009-1015.	1.5	131
12	Thrombotic risk factors: Basic pathophysiology. Critical Care Medicine, 2010, 38, S3-S9.	0.4	126
13	The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease. Blood, 2014, 123, 4037-4044.	0.6	123
14	Long-Term Evaluation of the Risk of Recurrence After Cerebral Sinus-Venous Thrombosis. Circulation, 2010, 121, 2740-2746.	1.6	120
15	Risk of Pregnancy-related Venous Thrombosis in Carriers of Severe Inherited Thrombophilia. Thrombosis and Haemostasis, 2001, 86, 800-803.	1.8	119
16	Usefulness of PFAâ€100® testing in the diagnostic screening of patients with suspected abnormalities of hemostasis: comparison with the bleeding time. Journal of Thrombosis and Haemostasis, 2007, 5, 2393-2398.	1.9	99
17	Circulating microparticles and risk of venous thromboembolism. Thrombosis Research, 2012, 129, 591-597.	0.8	92
18	The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both. British Journal of Haematology, 2000, 111, 1223-1229.	1.2	89

#	Article	IF	CITATIONS
19	Marburg I polymorphism of factor VII-activating protease and risk of venous thromboembolism. Blood, 2006, 107, 1731-1731.	0.6	73
20	High levels of factor VIII and risk of extra-hepatic portal vein obstruction. Journal of Hepatology, 2009, 50, 916-922.	1.8	69
21	Low Plasma Levels of Vitamin B ₆ Are Independently Associated With a Heightened Risk of Deep-Vein Thrombosis. Circulation, 2001, 104, 2442-2446.	1.6	67
22	Risk factors for postpartum hemorrhage in a cohort of 6011 Italian women. Thrombosis Research, 2012, 129, e1-e7.	0.8	64
23	Low borderline plasma levels of antithrombin, protein C and protein S are risk factors for venous thromboembolism. Journal of Thrombosis and Haemostasis, 2012, 10, 1783-1791.	1.9	63
24	The JAK2ÂV617F mutation in patients with cerebral venous thrombosis. Journal of Thrombosis and Haemostasis, 2012, 10, 998-1003.	1.9	61
25	Patients With Type 3 Severe von Willebrand Disease Are Not Protected Against Atherosclerosis. Circulation, 2004, 109, 740-744.	1.6	60
26	A 23bp Insertion in the Endothelial Protein C Receptor (EPCR) Gene Impairs EPCR Function. Thrombosis and Haemostasis, 2001, 86, 945-948.	1.8	56
27	Blood levels of homocysteine, folate, vitamin B6 and B12 in women using oral contraceptives compared to non-users. Thrombosis Research, 2003, 112, 37-41.	0.8	56
28	Risk factors for idiopathic sudden sensorineural hearing loss and their association with clinical outcome. Thrombosis Research, 2015, 135, 508-512.	0.8	54
29	Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. Annals of Oncology, 2004, 15, 590-593.	0.6	52
30	New approaches for measuring coagulation. Haemophilia, 2006, 12, 76-81.	1.0	52
31	Hemostatic Abnormalities in Noonan Syndrome. Pediatrics, 2014, 133, e1299-e1304.	1.0	49
32	Molecular diversity and thrombotic risk in protein S deficiency: The PROSIT study. Human Mutation, 2005, 25, 259-269.	1.1	48
33	VEGF Expression Correlates With Microvessel Density in Philadelphia Chromosome–Negative Chronic Myeloproliferative Disorders. American Journal of Clinical Pathology, 2007, 128, 966-973.	0.4	48
34	Management of Inherited <scp>v</scp> on Willebrand Disease in Italy: Results from the Retrospective Study on 1234 Patients. Seminars in Thrombosis and Hemostasis, 2011, 37, 511-521.	1.5	48
35	Platelet to Lymphocyte Ratio and Neutrophil to Lymphocyte Ratio as Risk Factors for Venous Thrombosis. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 808-814.	0.7	43
36	The relationship between plasma homocysteine levels and bone mineral density in post-menopausal women. European Journal of Internal Medicine, 2010, 21, 301-305.	1.0	42

#	Article	IF	CITATIONS
37	Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly. Experimental and Clinical Endocrinology and Diabetes, 2000, 108, 486-492.	0.6	35
38	Aging, menopause, cardiovascular disease and HRT. Climacteric, 2009, 12, 368-377.	1.1	35
39	Venous Thrombosis Risk after Cast Immobilization of the Lower Extremity: Derivation and Validation of a Clinical Prediction Score, L-TRiP(cast), in Three Population-Based Case–Control Studies. PLoS Medicine, 2015, 12, e1001899.	3.9	35
40	Association between red cell distribution width and risk of venous thromboembolism. Thrombosis Research, 2015, 136, 590-594.	0.8	34
41	Anticoagulant Treatment With Rivaroxaban in Severe Protein S Deficiency. Pediatrics, 2013, 132, e1435-e1439.	1.0	33
42	Low levels of protein Z and the risk of venous thromboembolism. Journal of Thrombosis and Haemostasis, 2005, 3, 2817-2819.	1.9	32
43	Cerebral Thrombosis and Myeloproliferative Neoplasms. Current Neurology and Neuroscience Reports, 2014, 14, 496.	2.0	32
44	The hemostatic system through aging and menopause. Climacteric, 2009, 12, 47-51.	1.1	30
45	Increased risk of venous thromboembolism in patients with bullous pemphigoid. Thrombosis and Haemostasis, 2016, 115, 193-199.	1.8	30
46	Normal reference ranges of antithrombin, protein C and protein S: Effect of sex, age and hormonal status. Thrombosis Research, 2013, 132, e152-e157.	0.8	29
47	Activation of Blood Coagulation in Two Prototypic Autoimmune Skin Diseases: A Possible Link with Thrombotic Risk. PLoS ONE, 2015, 10, e0129456.	1.1	28
48	Thrombophilic and cardiovascular risk factors for retinal vein occlusion. European Journal of Internal Medicine, 2017, 44, 44-48.	1.0	27
49	Budd-Chiari Syndrome in a Patient Heterozygous for the G20210A Mutation of the Prothrombin Gene. Thrombosis and Haemostasis, 1998, 79, 445-446.	1.8	26
50	Elevated prepartum fibrinogen levels are not associated with a reduced risk of postpartum hemorrhage. Journal of Thrombosis and Haemostasis, 2012, 10, 1451-1453.	1.9	24
51	High-d-dimer plasma levels predict poor outcome in esophageal variceal bleeding. Digestive and Liver Disease, 2008, 40, 874-881.	0.4	23
52	Towards the genetic basis of cerebral venous thrombosisâ€"the BEAST Consortium: a study protocol: TableÂ1. BMJ Open, 2016, 6, e012351.	0.8	23
53	Polymorphisms of the protein Z-dependent protease inhibitor (ZPI) gene and the risk of venous thromboembolism. Thrombosis and Haemostasis, 2006, 95, 909-910.	1.8	21
54	Coagulation testing before epidural analgesia at delivery: Cost analysis. Thrombosis Research, 2011, 128, 18-20.	0.8	20

#	Article	IF	Citations
55	Circulating and progenitor endothelial cells are abnormal in patients with different types of von Willebrand disease and correlate with markers of angiogenesis. American Journal of Hematology, 2011, 86, 650-656.	2.0	20
56	The "Pregnancy Health-care Program―for the prevention of venous thromboembolism in pregnancy. Internal and Emergency Medicine, 2015, 10, 129-134.	1.0	20
57	Probability Density Estimation Using Adaptive Activation Function Neurons. Neural Processing Letters, 2001, 13, 31-42.	2.0	19
58	Thrombophilic states. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 120, 1061-1071.	1.0	19
59	Pulmonary embolism in elderly patients: Prognostic impact of the Cumulative Illness Rating Scale (CIRS) on short-term mortality. Thrombosis Research, 2014, 134, 326-330.	0.8	19
60	Seasonal variation of venous thrombosis: a consecutive case series within studies from Leiden, Milan and TromsÃ, Journal of Thrombosis and Haemostasis, 2012, 10, 1704-1707.	1.9	18
61	Predictors of von Willebrand disease diagnosis in individuals with borderline von Willebrand factor plasma levels. Journal of Thrombosis and Haemostasis, 2015, 13, 228-236.	1.9	18
62	Factor V Leiden Mutation in Patients with Breast Cancer with a Central Venous Catheter: Risk of Deep Vein Thrombosis. Supportive Cancer Therapy, 2006, 3, 98-102.	0.3	15
63	Circulating endothelial cells (CECs) and progenitors (CEPs) in severe haemophiliacs with different clinical phenotype. British Journal of Haematology, 2009, 144, 803-805.	1.2	15
64	Pregnancy outcome after a first episode of cerebral vein thrombosis. Journal of Thrombosis and Haemostasis, 2016, 14, 2386-2393.	1.9	15
65	Red cell distribution width and the risk of cerebral vein thrombosis: A case–control study. European Journal of Internal Medicine, 2017, 38, 46-51.	1.0	15
66	Evaluation of the Utility of von Willebrand Factor Propeptide in the Differential Diagnosis of von Willebrand Disease and Acquired von Willebrand Syndrome. Seminars in Thrombosis and Hemostasis, 2019, 45, 036-042.	1.5	15
67	Increased glucose-dependent insulinotropic polypeptide (GIP) secretion in acromegaly. European Journal of Endocrinology, 2001, 145, R1-R4.	1.9	14
68	Endothelial protein C receptor plasma levels increase in chronic liver disease, while thrombomodulin plasma levels increase only in hepatocellular carcinoma. Thrombosis Research, 2007, 120, 289-293.	0.8	12
69	Influence of anticoagulant therapy with vitamin K antagonists on plasma levels of coagulation factor VIII. Thrombosis Research, 2010, 126, 243-245.	0.8	12
70	Identification of Four Novel Polymorphisms in the AÎ $_{\pm}$ and Î $_{3}$ Fibrinogen Genes and Analysis of Association with Plasma Levels of the Protein. Thrombosis Research, 2001, 103, 299-307.	0.8	11
71	Evaluation of an heterogeneous group of patients with von Willebrand disease using an assay alternative to ristocetin induced platelet agglutination. Journal of Thrombosis and Haemostasis, 2015, 13, 1806-1814.	1.9	11
72	Duration of oral contraceptive use and the risk of venous thromboembolism. A case-control study. Thrombosis Research, 2016, 141, 153-157.	0.8	11

#	Article	IF	CITATIONS
73	High Levels of Vascular Endothelial Growth Factor Protein Expression Are Associated With an Increased Risk of Transfusion Dependence in Myelodysplastic Syndromes. American Journal of Clinical Pathology, 2013, 139, 380-387.	0.4	10
74	Genomeâ€Wide Association Study Identifies First Locus Associated with Susceptibility to Cerebral Venous Thrombosis. Annals of Neurology, 2021, 90, 777-788.	2.8	10
75	Influence of proband's characteristics on the risk for venous thromboembolism in relatives with factor V Leiden or prothrombin G20210A polymorphisms. Blood, 2013, 122, 2555-2561.	0.6	9
76	Psychological impact of thrombosis in the young. Internal and Emergency Medicine, 2006, 1, 119-126.	1.0	8
77	Fibrinogen Milano XIII (Aα 19 Arg→Gly). Thrombosis Research, 1999, 96, 399-405.	0.8	6
78	The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both. British Journal of Haematology, 2000, 111, 1223-1229.	1.2	6
79	Low risk of thrombosis in family members of patients with hyperhomocysteinaemia. British Journal of Haematology, 2002, 117, 709-711.	1.2	6
80	Incidence and Determinants of Bleeding in Different Types of von Willebrand Disease: Results of the First Prospective Multicenter Study on 814 Italian Patients Blood, 2007, 110, 713-713.	0.6	6
81	Effect of prothrombin 19911 A>G polymorphism on the risk of cerebral sinusâ€venous thrombosis. European Journal of Neurology, 2010, 17, 1482-1485.	1.7	4
82	Baseline factor <scp>VIII</scp> plasma levels and age at first bleeding in patients with severe forms of von Willebrand disease. Haemophilia, 2016, 22, 564-569.	1.0	4
83	Reply:. Hepatology, 2007, 45, 832-833.	3.6	1
84	IgG subclasses as biomarkers for persistence of factor VIII inhibitors in previously untreated patients with severe haemophilia A. British Journal of Haematology, 2021, 192, 621-625.	1.2	1
85	Reply to a Rebuttal: Counseling Pregnant Women Homozygous for Factor V Leiden. Thrombosis and Haemostasis, 2002, 87, 361-361.	1.8	0
86	Hematological evaluation of acquired von Willebrand syndrome before oral surgery: Management of an unusual case. Asian Journal of Transfusion Science, 2012, 6, 46.	0.1	0
87	Occult Cancer and Venous Thromboembolism. Thrombosis and Haemostasis, 1998, 80, 347-348.	1.8	0